<DOC>
	<DOCNO>NCT00281645</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy bicifadine 400 mg BID one year patient moderate severe chronic low back pain . The secondary objective compare long-term safety bicifadine standard care therapy , evaluate safety bicifadine follow discontinuation dose , evaluate safety efficacy low dos bicifadine patient tolerate bicifadine 400 mg BID .</brief_summary>
	<brief_title>Long-Term Safety Study Bicifadine Treatment Chronic Low Back Pain</brief_title>
	<detailed_description>There two way subject could enter study . Subjects complete 12 week treatment two double blind clinical study bicifadine ( Studies 020 021 , United States ) could roll study . Also , de novo subject ( , subject previously receive bicifadine ) could enroll study .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Main Patients low back pain assess Class 1 , Class 2 Class 3 accord Quebec Task Force Classification Spinal Disorders without detectable leg weakness neurological examination . Patients must require average daily analgesic treatment low back pain past 3 month prior screen . Main Patients may moderate severe pain location low back ( exception radiation low extremity ) weakness low extremity . Patients must epidural corticosteroid injection low back within 1 month prior baseline . Patients may unstable medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>